Location preference

Enter your country so we can show you products that are available for you.

Spectra Optia Depletion Protocol

Supporting depletion therapy with Spectra Optia

The Spectra Optia™ Apheresis System from the team at Terumo Blood and Cell Technologies can be used for automated depletion therapy. Below you'll find details about the protocols for white blood cell depletion (WBCD) and platelet depletion.* If you have questions, please reach out to our apheresis device and procedure experts.

Depletion

White blood cell depletion (WBCD) and platelet depletion

Whether you need to perform a WBC or platelet depletion procedure, the advanced Spectra Optia system is designed to provide choice and precision.

Procedure information

  • Maintains depletion efficiency at a range of inlet pump flow rates by automatically adjusting the collect pump flow rate
  • Allows you to target a specific fluid balance without manual calculations using integrated fluid balance management
  • Establishes the appropriate packing factor automatically with an intuitive hydroxyethyl starch (HES) option
  • Typical extracorporeal volume (ECV) is 253 mL; maximum ECV is 297 mL**   

 Graphical user interface (GUI) for WBCD

Featured resources

See how the Spectra Optia system can be the solution to your apheresis and cell collection needs.

Explore other protocols available on Spectra Optia

Spectra Optia protocols
Exchange
Spectra Optia protocols
Collection
Spectra Optia protocols
Processing

Contraindications

  • There are no known contraindications for the system's use, except for those associated with all automated apheresis systems.
  • The infusion of certain solutions and replacement fluids may be contraindicated in some patients.

Possible patient reactions

  • Anxiety, headache, light-headedness, digital and/or facial paresthesia, fever, chills, hematoma, hyperventilation, nausea and vomiting, syncope (fainting), urticaria, hypotension, and allergic reactions.

Reactions to transfused blood products can include1

  • Fever, circulatory overload, shock, allergic reactions, alloimmunization, graft-versus-host disease, and transmission of infection.

Restricted to prescription use only

  • Operators must be familiar with the system's operating instructions.
  • Procedures must be performed by qualified medical personnel.
  • A supervisory practitioner may supervise from a physician office or other nonhospital space that is not officially part of the hospital campus as long as he or she remains immediately available.2

Disclaimers and notes

*Product and protocol availability varies by country. The white blood cell depletion (WBCD) and platelet depletion protocol is not approved in the United States. Contact your Terumo Blood and Cell Technologies representative for more information.

**Under normal operating conditions, the ECV will not exceed the typical ECV value. Under certain infrequent alarm conditions, such as during reservoir recovery after a reservoir alarm, the ECV may momentarily increase to the maximum ECV value.

1. AABB (ed.), et al. Circular of Information for the Use of Human Blood and Blood Components. 10th ed. 2006; Council of Europe Publishing, Seattle, WA.

2. American Society for Apheresis. Guidelines for documentation of therapeutic apheresis procedures in the medical record by apheresis physicians. J Clin Apher. 2007; 22(3):183.

 

To top